Amarin, HLS Therapeutics present REDUCE-IT, EPA mechanistic data

Amarin (AMRN) in collaboration with its Canadian partner HLS Therapeutics announce the presentation of scientific data at the upcoming Canadian Cardiovascular Congress, CCC, taking place in Quebec City, Quebec, Canada from October 23 to 26, 2025. These presentations reflect the continued commitment of Amarin and HLS to advancing the broader therapeutic potential of Icosapent Ethyl, IPE, and Eicosapentaenoic Acid, EPA, further highlighting their dedication to improving cardiovascular care for appropriate patients. Data to be presented at CCC 2025 highlights the clinical value of IPE for cardiometabolic conditions as well as further attempts to explore the mechanistic effects of EPA on atherogenic lipoproteins and in endothelial cells during inflammation when combined with a GLP-1 receptor agonist.